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Abstract
Highly selective therapy for hepatocellular carcinoma (HCC) remains an unmet medical need. In present study, we found
that the tumor suppressor microRNA, let-7 was significantly downregulated in a proportion of primary HCC tissues (12 of 33,
36.4%) and HCC cell lines. In line with this finding, we have engineered a chimeric Ad5/11 fiber oncolytic adenovirus,
SG7011
let7T, by introducing eight copies of let-7 target sites (let7T) into the 39 untranslated region of E1A, a key gene
associated with adenoviral replication. The results showed that the E1A expression (both RNA and protein levels) of the
SG7011
let7T was tightly regulated according to the endogenous expression level of the let-7. As contrasted with the wild-type
adenovirus and the control virus, the replication of SG7011
let7T was distinctly inhibited in normal liver cells lines (i.e. L-02 and
WRL-68) expressing high level of let-7 (.300 folds), whereas was almost not impaired in HCC cells (i.e. Hep3B and PLC/PRF/5)
with low level of let-7. Consequently, the cytotoxicity of SG7011
let7T to normal liver cells was successfully decreased while was
almost not attenuated in HCC cells in vitro. The antitumor ability of SG7011
let7T in vivo was maintained in mice with Hep3B
xenograft tumor, whereas was greatly decreased against the SMMC-7721 xenograft tumor expressing a high level of let-7
similar with L-02 when compared to the wild-type adenovirus. These results suggested that SG7011
let7T may be a promising
anticancer agent or vector to mediate the expression of therapeutic gene, broadly applicable in the treatment for HCC and
other cancers where the let-7 gene is downregulated.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third most common cause of death from
cancer, resulting in more than 600,000 deaths each year [1]. As
surgical techniques have progressed, hepatic resection has evolved
into a safe procedure with low operative mortality at large centers
[2]. However, no more than 20% of patients with HCC have
opportunity to undergo surgery procedures. Chemotherapy and
radiotherapy are beneficial complementarities for HCC treat-
ments, yet they lack of tumor specificity and have limited efficacy
to the majority of HCC patients at an advanced stage [3]. Thus, it
is of importance to seek cancer-specific therapeutic targets and
develop effective alternative approaches to specifically treat against
HCC.
MicroRNAs (miRNAs) are versatile, noncoding RNAs, which
exert posttranscriptional regulation by targeting mRNAs through
specific recognition of short sequences, leading to decreased
protein production [4]. It has been well documented that miRNA
is expressed in tissue- and differentiation state-specific patterns and
plays an important role in the control of mammalian growth and
development [5]. The let-7 miRNA is one of the first known
microRNAs, originally discovered in the nematode Caenorhabditis
elegans, where it regulates cell proliferation and differentiation [6].
Subsequent work has shown that let-7 is highly conserved across
species and found abundantly and ubiquitously expressed in
mammalian cells [7]. Conversely, increasing evidence has revealed
that let-7 is deregulated in various cancer cells, such as colorectal
cancer [8], lung cancer [9], colon cancer [10], ovarian cancer
[11], breast cancer [12], gastric cancer [13], malignant melanoma
[14], Burkitt lymphoma [15], and acute lymphoblastic leukemia
[16]. Recently, it have been reported that members of let-7 family
are downregulated in hepatocellular carcinoma [17–20].
Given its characteristic in cancer cells, let-7 might serve as an
ideal candidate or tool for cancer therapy [21]. Previous studies
have validated that in vitro or in vivo let-7 restorations can inhibit
tumor growth [22]. However, like other miRNA replacement or
antagonizing therapies, it remains a challenge to effectively deliver
the let-7 into cancer cells in vivo [23]. As an alternative, the miRNA
system is also possible to be used as a tool to control the tropism of
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virotherapeutics [24]. Due to its tissue-specific expression profile
and short targeting site, miRNA provides considerable flexibility in
the design of conditionally replicative viruses. By introduction of
miRNA target sequence into the 39-untranslated region (UTR) of
a key gene that has an essential role in viral growth and
replication, the virus replication can be controlled by the tissue-
specific endogenous miRNA, thus eliminating the unwanted
pathology of wild-type virus [25–28].
There are currently four oncolytic viruses in phase III trials.
Experts in the field believe that an approved product of this new
kind of therapeutics is on the horizon [29]. Oncolytic adenovirus
holds great promise in anticancer virotherapeutics because of its
inherent ability to directly destroy cancer cells and mediate
effective transgenic expression in the process of viral production
[30]. Previously, diverse schemes have been developed to engineer
specificity and improve safety of virotherapy strategies with
oncolytic adenovirus, among which are involvement of the E1B
deletion [31] or E1A mutation [32], introduction of tumor- or
tissue-specific promoters to control the expression of E1A or/and
E1B [33–35], utilizing liver-specific miR-122a to regulate E1A
expression [27], and genetic modification of the adenoviral capsid
to change the adenovirus tropism [36–38]. Unfortunately,
systemic administration of adenoviruses can cause significant
infection of hepatocytes and may lead to liver toxicity [39].
Therefore, it remains a challenge to selectively target the cancer
cells and leaving the normal cells, especial normal liver cells
unharmed in the therapeutic use of oncolytic adenovirus for HCC.
In this study, we detected the expression of let-7 family in a set
of primary HCC tissue and HCC cell lines. In line with the finding
that let-7 is downregulated in a considerable proportion of primary
tissues (36.4%) and HCC cells, we have demonstrated the
possibility of using let-7 to fine-tune the replication specificity of
a chimeric Ad5/11 fiber adenovius, thereby reducing Ad’s
hepatotoxicity while maintaining its therapeutic replication within
HCC cells.
Results
Downregulation of Let-7 in Primary HCC Tissues and HCC
Cell lines
Expression of let-7a, a member of let-7 family, in 33 primary
HCC tissues was measured by SYBR Green Real-time RT-PCR.
Most samples were collected from patients suffered cirrhosis (22/
33, 66.7%) and had positive HBsAg (20/33, 60.1%). The results
indicated that let-7a expression was decreased in 12 (36.4%, .2
folds) HCC samples compared to adjacent normal liver while
increased in 6 (18.2%, .2 folds), and showed no significant
difference in other 15 (45.4%, ,2 folds). Furthermore, the let-7a
was decreased more than 5 folds in 10 samples (30.3%) and
decreased more than 20 folds in 4 samples (12.1%). However, no
data was revealed that let-7a expression was correlated with the
age, gender, tumor size, Hepatitis B infection, or cirrhosis of the
HCC patients (Table 1).
Then we investigated let-7a expression in a series of HCC cell
lines. The results showed that let-7a was significantly down-
regulated in HepG2 (0.066), Hep3B (0.021), and PLC/PRF/5
(0.010) cell lines as compared with normal liver cell line, L-02
(1.000) and WRL-68 (0.703), while it was slightly down-regulated
in Huh7 (0.834) and SMMC-7721 (0.941) cell lines (Fig. 1). The
two fibroblast lines (MRC-5 and BJ) showed relative higher level of
let-7a expression. Other members of let-7 family (i.e. let-7b, let7c,
let-7d, let-7e, let-7f, and let-7g) were also downregulated at some
extent in these HCC cell lines. These results indicated that total
expression of let-7 family was decreased in a considerable
proportion of primary HCC tissues and HCC cell lines.
Let-7 Target Sites Effectively Regulate the Upstream
Gene According to Endogenous Let-7
To assess the ability of let-7 in suppressing foreign genes, a let-
7-sensitive (psiCHECK2-let7T) (containing eight copies of
imperfectly complementary let-7 target sites) and a let-7-
insensitive (psiCHECK2-let7MT) (containing eight copies of
‘‘seed’’-mutated let-7 target sites) luciferase reporter vector was
generated and measured the effect of let-7 target sites (let7T) in
high (L-02) versus low (Hep3B) let-7-containing cell lines. The
results showed that RLuc/FLuc value was 8.7% in psiCHECK2-
let7T transfected L-02 cells and 91% in same treated Hep3B
cells when individually normalized to that of psiCHECK
TM-2
transfected cells (Figure 2). By contrast, the RLuc/FLuc value
was 86.0% and 87.8% in psiCHECK2-let7MT transfected L-02
and Hep3B cells, respectively (Fig. 2), confirming that the
inhibitory effect was indeed mediated by the endogenous let-7.
These results demonstrated that eight copies of let-7 target sites
could effectively regulate the expression of the upstream gene
according to the cellular endogenous expression status of the
let-7 gene.
Cellular Let-7 Controls the Expression of E1A in the
Let-7-engineered Adenovirus
Having identified the capacity of let-7 target sites in the
regulation of the upstream gene, a let-7-regulated fiber chimeric
adenovirus, SG7011
let7T, was constructed by incorporating the
same fragment containing eight copies of let-7 target sites
immediately after the stop codon of E1a gene and substituting
the Ad5 fiber protein with the Ad11 knob domain (Fig. 3A). At the
same time, the fragment containing eight copies of ‘‘seed’’-
mutated let-7 target sites were individually inserted into the same
site to generate a control fiber chimeric adenovirus, SG7011
let7MT.
Table 1. Univariate Analysis of let-7a Expression and
Clinicopathological Risk Factors in Patients with HCC.
Total
relative let-7
expression
a
r
b P
$2 (0.5, 2) #0.5
Age (years) $55 15 1 8 6 0.193 0.281
,55 18 5 7 6
Gender male 29 6 14 9 0.295 0.096
female 4 0 1 3
Tumor size (cm) $5 20 4 11 5 0.142 0.431
,51 3 2 5 7
Tumor grade 2 6 0 4 2 0.1 0.581
32 7 6 1 11 0
HBsAg (+) 20 3 7 10 0.235 0.189
(-) 13 3 8 2
Cirrhosis (+) 22 4 9 9 0.09 0.619
(-) 11 2 6 3
aThe let-7a expression of primary HCC tissues relative to normal liver tissues.
bThe correlation coefficient between types of each clinicopathological risk
factors and the three status of let-7a expression (i.e. decreased, increased, or
unaltered).
doi:10.1371/journal.pone.0021307.t001
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in regulating adenoviral E1A expression in HCC cells and normal
liver cells. The results showed that within normal liver cell lines
that have high cellular let-7, the E1A protein was dramatically
suppressed in the SG7011
let7T-infected cells, but remained highly
expressed in the SG7011
let7MT- and WAd5-infected cells. In HCC
cell lines that have low cellular let-7, however, the E1A protein
expressed similarly among the SG7011
let7T-, SG7011
let7MT- and
WAd5-infected cells (Fig. 3B).
Since let-7 has been documented to mediate mRNA dead-
enylation via binding on its imperfectly complementary target sites
[40], we next measured the amount of E1A mRNA in
SG7011
let7T-, SG7011
let7MT- and WAd5-infected cells by quan-
titative RT-PCR. In good agreement with the Western blotting
data, E1A mRNA levels in SG7011
let7T-infected L-02 and WRL-
68 cells were significantly lower than those in SG7011
let7MT- and
WAd5-infected corresponding cells, whereas in Hep3B and PLC/
PRF/5 cells, the viruses expressed similar amounts of E1A mRNA
(Fig. 3C). These results indicated that the negative regulation of
cellular let-7 on E1A may through mRNA destruction.
Replicative Control of Recombinant Adenovirus by let-7
Target Sites
Viral replication was detected to evaluate the capacity of let-7
target sites in regulating the adenoviral replication in HCC cells
and normal liver cells. The results showed that the testing virus,
Figure 1. Quantitative measurement of let-7a expression by SYBR Green Real-time PCR. The U6 was used as an endogenous control and
L-02 was used as a reference sample. Error bars correspond to mean 6 SD. n=3.
doi:10.1371/journal.pone.0021307.g001
Figure 2. The regulation effect of let-7 target sites on upstream gene, analyzed by dual-luciferase assay system. The relative Renilla/
Firefly ratio of cells transfected with the control plasmid, psiCHECK2 was set to 100%. The Renilla/Firefly values of cells transfected with psiCHECK2-
Let7T or psiCHECK2-Let7MT was normalized to its corresponding value of cells transfected with psiCHECK2 in a same independent experiment,
respectively. Duplicated experiments were conducted from the procedure of cell culture. Error bars correspond to mean 6 SD. n=3. (
** P,0.01).
doi:10.1371/journal.pone.0021307.g002
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let7T, replicated preferably in HCC cells but significantly
decreased in normal liver cells (p,0.01) (Fig. 4A). Conversely, the
control virus, SG7011
let7MT was replicated in both normal liver
cells and HCC cells, showing a viral tropism similar with that of
wild-type adenovirus (Fig. 4A). The replication of SG7011
let7T
decreased at lest 300-fold than that of SG7011
let7MT and WAd5 in
normal liver cells, whereas almost not attenuated in HCC cells.
These results indicated that the introduced let-7 target sites could
effectively control adenoviral replication according to the
expression of cellular endogenous let-7.
Alternatively, we determined the selective replication of
SG7011
let7T in normal liver and HCC cells via SG7011
let7T-
EGFP, a recombinant adenovirus carrying EGFP gene. The
results observed here were consistent with those from the
evaluation of viral replication. In L-02 cells, only a few scattered
cells emitted fluorescence 3 days post infection and this status
also persisted for 7–10 days since infection (Fig. 4B). However, in
t h eH e p 3 Bc e l l s ,t h ef l u o r e s c e n c ee m e r g e df r o mas i n g l ec e l lt o
many surround cells and simultaneously more and more cells
died with EGFP degradation 7 or 10 days post infection. In
c o n t r a s t ,i nb o t hL - 0 2a n dH e p 3 Bc e l l si n f e c t e dw i t h
SG7011
let7MT-EGFP or WAd5-EGFP, the fluorescence gradu-
ally increased and some cells died with EGFP degradation from
3 to 10 days post infection.
Let-7 Target Sites Reduce Hepatic Toxicity of
Recombinant Adenovirus while Remain its Oncolytic
Effects on HCC Cells in vitro
Since the engineered adenovirus SG7011
let7T was replicated
preferentially in tumor cells where the let-7 is downregualted, its
cytotoxic effects in normal liver and HCC cells were quantified by
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. The results showed that the hepatic toxicity of
SG7011
let7T was significantly decreased as compared to that of
WAd5 (p,0.01) (Fig. 5). Seven days after the SG7011
let7T
infection at MOI of 1000 pfu/cell, the viability of L-02 and
WRL-68 cells remained 87.4% and 86.0%, respectively. In
contrast, in WAd5-infected L-02 cells, the cell viability was
52.9% at MOI of 20 pfu/cell, and 15.5% at an MOI of 1000 pfu/
cell. In WAd5-infected WRL-68 cells, the cell viability was 37.0%
and 28.7% at MOI of 500 pfu/cell and 1000 pfu/cell, respec-
tively. The control virus, SG7011
let7MT had similar cytotoxicity to
normal liver cells, showing IC50 (MOI values of 50% viability) at
Figure 3. The capacity of let-7 target sites to regulate E1A expression of the recombinant adenovirus, SG7011
let7T. (A) Virus
construction. Eight copies of let-7 target sites were inserted into the 39UTR of E1A gene and the Ad5 fiber was replaced by Ad5/11 chimeric fiber. ITR,
inverted terminal repeats. (B) Detection of E1A protein expression by Western Blotting. The 1, 2, 3 lane represented cells infected with WAd5,
SG7011
let7T and SG7011
let7MT, respectively. PLC, PLC/PRF/5. (C) Detection of E1A mRNA expression by quantitative RT-PCR. The gene of GAPDH was
used as an endogenous control and HEK293 cell uninfected with adenovirus was used as a reference sample. Let7T, SG7011
let7T; Let7MT,
SG7011
let7MT. Error bars correspond to mean 6 SD. n=3. (
** P,0.01).
doi:10.1371/journal.pone.0021307.g003
Let-7 Fine-Tunes Adenovirus Targeting to HCC
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e2130720 and 500 pfu/cells in L-02 and WRL-68 cells, respectively. In
HCC cell lines, however, SG7011
let7T showed similar oncolytic
effect with WAd5 and SG7011
let7MT. The IC50 of SG7011
let7T,
WAd5, and SG7011
let7MT was all between 0.01 and 0.05 pfu/cell
in Hep3B cells, and between 0.5 and 1.0 pfu/cell in PLC/PRF/5
cells.
Introduction of Let-7 Target Sites does not Attenuate
Oncolytic Effects of Recombinant Adenovirus on HCC
Cells in vivo
The antitumor efficacy of SG7011
let7T as a monotherapy was
evaluated in two kinds of s.c. xenograft HCC tumor model (i.e.
Hep3B and SMMC-7721). In Hep3B xenografts model, a tumor
model with low level of let-7, significant antitumor efficacy was
observed. By day 28, the placebo treated tumors had increased 10-
fold in volume whereas the SG7011
let7T treated tumors as a
concentration of WAd5 pfu per dose grown a little in size (1.6 fold
of the day 1 volume) (Fig. 6A). These results indicated that the
antitumor effect of SG7011
let7T was closed to that of WAd5 in
Hep3B xenografts models. Conversely, in the SMMC-7721
xenografts models, a tumor model containing let-7 at a level
corresponding to normal hepatocytes, almost no antitumor effect
was displayed in the SG7011
let7T treatment. The curve of tumor
growth in the SG7011
let7T-treated group was similar with that of
placebo control while significantly different from the WAd5-
treated one (Fig. 6A), assuming that the cytotoxicity of wild-type
adenovirus to normal liver might be eliminated in the engineered
adenovirus SG7011
let7T.
The tumor samples were examined histologically by H&E
staining and immunohistochemical staining for hexon protein. For
the Hep3B tumor, the cancer cells grew luxuriantly with small foci
of necrosis in the control group, whereas many wide areas of
necrosis were observed and hexon protein was detected in the both
WAd5- and SG7011
let7T-treated groups (Fig. 6B). For the SMMC-
7721 tumor, few necroses were observed in the SG7011
let7T-
treated group and the signal of hexon protein was weak, which was
remarkably different from the situation of the WAd5-treated
Figure 4. The capacity of let-7 target sites in regulation of virus replication. (A) Viral replication assay. Cells were planted in 6-well dishes
(10
6 cells/well) and infected with indicated viruses at a MOI of 5 pfu/cell, and the cell lysates and supernatant at 48 h post infection were tittered by
the TCID50 method in HEK293 cells and normalized to those at the beginning of infection. Let7T, SG7011
let7T; Let7MT, SG7011
let7MT. (B) Fluorescence
analysis. The L-02 and Hep3B cells were infected with test or control virus at an MOI of 0.01 and 0.001, respectively. Three days (3D), 7 days (7D), and
10 days (10D) post infection, cells were observed under fluorescent microscope and photos were taken. The WAd5, let7T, and let7MT represented
WAd5-EGFP, SG7011
let7T, and SG7011
let7MT, respectively. Bar=10 mm.
doi:10.1371/journal.pone.0021307.g004
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let7T
could efficiently lyse tumor cells with lower level of let-7, leaving
normal liver cells with higher level of let-7 spared.
Discussion
It has been well documented that members of let-7 family play
important roles in both normal development and tumorigenesis
[41]. In normal stem cells, let-7 can negatively regulate ‘‘stemness’’
by repressing self-renewal and promoting differentiation [21].
Consistent with its role of tumor suppressor, let-7 is found
deregulated in various forms of cancers and the decreased
expression of let-7 is functionally linked to tumor cell biology,
paralleled with the upregulated expression of proto-oncogenes,
reflecting poor patient prognosis at least in lung cancers [21].
More interestingly, it has been demonstrated that let-7 is markedly
reduced in breast tumor initiator cells, regulating their self-renewal
and tumorigenicity [42]. Here we reported that let-7 was
downregulated (.2 folds) in a proportion of primary HCC tissues
(12/33, 36.4%), most which were collected from patients had a
history of HBV infection and suffered cirrhosis (Table 1).
Moreover, ten HCC tissues (10/33, 30.3%) even had deregulated
let-7 which was more than 5 folds lower relative to their
corresponding normal liver tissues. This result was consistent with
the finding from recent work via deep-sequencing, showing that
the abundance of several members of let-7 family were among the
top 10 most abundantly expressed miRNAs in normal livers and
the abundance of let-7 remarkably decreased (.10 folds) in a
considerable proportion of HCC tissues as compared with
matched normal liver tissues. To date, however, the underlying
mechanism for the repression of let-7 in HCC remains unknown.
The upregulation of LIN28B [43,44], a suppressor of let-7
expression, may be one of possible causes. Furthermore, since
the constitute of HCC tissue is highly heterogeneous, it is unclear if
the lower levels of let-7 in HCC tissue vs. normal liver tissue were
due to transformation of hepatocytes or differences in the relative
abundance of other cell types in these paired tissues specimens.
The strategy using tissue-specific microRNAs to modify virus
tropism has been exploited in several types of oncolytic virus [24].
To adenovirus, the liver-specific miR-122a has been introduced to
Figure 5. The cytotoxicity of recombinant adenovirus to normal liver cells and HCC cells in vitro, analyzed by MTT assay. Cell viability
of L-02, WRL-68, Hep3B, and PLC/PRF/5 were infected with WAd5, SG7011
let7T, and SG7011
let7MT at various MOIs were measured on day 7
postinfection by MTT assay. Let7T, SG7011
let7T; Let7MT, SG7011
let7MT. Error bars correspond to mean 6 SD. n=3.
doi:10.1371/journal.pone.0021307.g005
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hepatotoxicity of wild-type adenovirus [28]. Taken together the
data presented here, it indicates that microRNA-based regulation
strategy alone is effective to control the adenovirus tropism.
Furthermore, due to its specific insertion sites (39-untranslated
region) and special regulation stage (post transcription), the
strategy can also be combined with other virus regulation
approach, such as promoter control, deletion/mutation control,
and capsid modification. In fact, as an example, the miR-122a-
meadiated regulation via three miR-122a target sites downstream
E1A gene and another regulation approach based on CR2-
deletion targeting to Rb-deficient cancer cells has been successfully
combined to fine-tune oncolytic adenoviruses [27]. Moreover, this
strategy introduces no mutation in virus protein, leaving virus
packaging efficiency unharmed and thus without attenuation of
adenovirus’s ability to kill cancer cells. Such a view has been
Figure 6. Potent antitumor activity on hepatocellular carcinoma xenografts with SG7011
let7T. (A) Measurement of antitumor activity.
BALB/c nude mice (n=10 per group) bearing Hep3B or SMMC-7721 xenografts were treated with WAd5, SG7011
let7T, and virus preservation buffer
control by i.t. administration five times at a dosing volume of 100 ml( 5 610
8 pfu), on the days of 1, 3, 5, 7 and 9 following the initiation. Tumor volume
was estimated with the formula: (maximal diameter)6(perpendicular diameter) 260.5. Error bars correspond to mean 6 SD. (B) Pathologic
examination of Hep3B or SMMC-7721 tumor xenografts. The necrosis areas in HE staining was indicated by thin arrow and the area showing positive
signal in immunohistochemistry staining with anti-hexon antibodies was indicated by bold arrow. (6400) Let7T, SG7011
let7T.
doi:10.1371/journal.pone.0021307.g006
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[27,28]. Hence, the viral regulation strategy based on tissue-
specific microRNA (including normal tissue specific-expressed and
cancer tissue specific-suppressed) is promising to generate
conditionally replicative adenoviruses.
Since let-7 is expressed at lower levels in HCC cells than normal
liver cells and can affect either the stability or translation of the
target mRNA [40], it is feasible to decrease the Ad’s liver tropism
via introducing let-7 target sites to regulate E1A expression. As
shown above, both mRNA and protein of the E1A was tightly
regulated according to cellular let-7. Consequently, the replication
of the engineered virus was decreased more than 300-fold
compared to the control virus in normal liver cells, whereas the
proliferation rate between the engineered virus and the control
virus was similar in HCC cells. Accordingly, the cytotoxicity of the
engineered virus was distinctly declined in normal liver cells while
alomst not impaired in HCC cells. These results indicated that
introduction of let-7 target sites downstream of E1A could
successfully decrease the hepatotoxicity of wild-type adenovirus
without attenuation of its ability to kill HCC cells with lower level
of let-7. Thus, the engineered adenovirus fine-tuned by let-7
presented here may serve as a potential anticancer agent or a
therapeutic vehicle for harboring antitumor genes, broadly applied
in the treatment against cancer with the downregulated cellular
let-7, including HCC.
Materials and Methods
Patients and Sample Collection
Thirty-three pairs of primary hepatocellular carcinoma (HCC)
tissues and corresponding adjacent normal liver tissues were used.
All clinical samples were collected with the approval of Ethnics
Committee of Eastern Hepatobiliary Surgery Hospital and written
informed consent from HCC patients undergoing surgery.
Pathological diagnosis was made according to the histology of
tumor specimens and examinations were performed by experi-
enced pathologists. All cancer tissue samples were grossly dissected
and snap-frozen in liquid nitrogen within 20 min of removal and
stored at 280uC until RNA extraction.
Cell Culture
Human HCC cell lines (HepG2, Hep3B, PLC/PRF/5, Huh7),
human embryonic liver cell line WRL-68, fibroblast lines (MRC-5
and BJ), and human embryo kidney cell line (HEK293) were
purchased from the ATCC (Manassas, VA). The human HCC cell
line (SMMC-7721) and the human normal liver cell line (L-02,
also designated as HL-7702) were obtained from the Institute of
Cell Biology, Chinese Academy of Sciences (Shanghai, China). All
cell lines were cultured according to the instructions of the
providers.
Real-time RT-PCR
Total RNA was isolated using a miRNeasy mini kit (Qiagen,
Valencia, CA) and reverse transcriptase reactions were performed
using a miScript Reverse Transcription Kit (Qiagen, Valencia,
CA). The expression of let-7 family was measured by miScript
SYBR Green PCR Kit (Qiagen, Valencia, CA) according to the
manufacturers’ protocol and normalized to U6 levels. The relative
expression values of different cells or samples were determined by
using L-02 cell as a reference sample. E1A expression in
adenovirus infected cells was measured and quantified by SYBR
Green Realtime PCR Kit (ToYobo, Osaka, Japan) according to
the manufacturers’ protocol, using GAPDH as an endogenous
control and HEK293 as a reference sample.
Preparation of Luc Reporter Plasmids and Luciferase
Assays
Eight copies of imperfectly complementary let-7 target sites
(AACTATACAACGTCTACCTCA) [45] or ‘‘seed’’-mutated let-
7 target sites (AACTATACAACGTCTTGGAGT) with 2–6
oligonucleotides intervals were synthesized (TAKARA, DaLian,
China)and cloned downstream of the Renilla luciferase gene of
psiCHECK
TM-2 (Promega, Madison, WI), a plasmid containing
both Renilla luciferase (RLuc) and firefly luciferase (FLuc) reporter
gene, to generate reporter plasmids sensitive to let-7 (i.e.
psiCHECK2-let7T), and control plasmid insensitive to let-7 (i.e.
psiCHECK2-let7MT). L-02 or Hep3B cells in 12-well plates were
transfected with 5 ng of psiCHECK-2, psiCHECK2-let7T, or
psiCHECK2-let7MT by using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Twenty-four hours posttransfection, values of
relative luciferase activity (RLuc/FLuc) were measured using the
dual-luciferase assay system (Promega, Madison, WI). Duplicated
experiments were conducted starting from the procedure of cell
culture and either RLuc/FLuc value for the psiCHECK2-let7T or
psiCHECK2-let7MT constructs was normalized to its correspond-
ing value for the psiCHECK2 constructs in a same independent
experiment, respectively.
Viral Construction
pXC-miR was constructed from adenovirus shuttle plasmid,
pXC.1 (Microbix Biosystems Inc., Toronto, Canada) by overlap
PCR to introduce one BstBI and one SalI restriction site
immediately after the stop codon of E1a gene. And then, DNA
fragment containing eight copies of let-7 target sites or seed-
mutated let-7 target sites mentioned above was inserted into pXC-
miR between BstBI and SalI site to generate pXC-let7T and pXC-
let7MT, respectively. pPE11 is a adenovirus packaging plasmid
derived from pBHGE3 and pBHGlox DeltaE1.3 (Microbix
Biosystems Inc.) constructed by replacing Ad5 fiber with Ad5/
F11 chimeric fiber using the same procedure as described in our
previous publication [33]. Finally, the plasmids pXC-let7T, pXC-
let7MT, and pXC.1 were individually transfected into HEK293
cells using Effectene Transfection Reagent (Qiagen, Valencia, CA)
together with pPE11. The obtained chimeric adenovirus was
named as SG7011
let7T, SG7011
let7MT, and WAd5, respectively.
Western Blot Analysis
L-02, HepG2, Hep3B, and PLC/PRF/5 cells were seeded in six
well plates at a density of 5610
5 per well, cultured for 24 h, and
infected with viruses at a MOI of 5 pfu/cell. Two days later, cells
were harvested and lysed by using M-PER Mammalian Protein
Extraction Reagent (PIERCE, Rockford, Ill). Total protein (20 mg)
was separated on 10% SDS-polyacrylamide gel and electroblotted
onto PROTRAN nitrocellulose transfer membrane (Schleicher &
Schuell, Dassel, Germany) and carried out Western blot by using
the mouse anti-adenoviral E1a antibody M73 (Santa Cruz
Biotechnology, CA) and the horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Cell Signaling Technology,
Beverly, MA). The signals were visualized with LumiGLO
chemiluminescent reagent and peroxide (Cell Signaling Technol-
ogy).
Viral Replication Study
Human HCC cell lines (HepG2 and Hep3B) and normal liver
cell lines (L-02 and WRL-68) were seeded in six-well plates at
5610
5 cells per well and cultured until cancer cells were in log
phase and normal cells at contact inhibition stage. Subsequently,
the cultured cells were infected with the adenoviruses,
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let7T, SG7011
let7MT and WAd5 at a multiplicity of
infection of 5 (MOI=5). Forty-eight post infection, the cells were
harvested and lysed by three cycles of freeze and thaw, and their
viral titers were examined with the tissue culture infectious dose 50
(TCID50) methods as described in our previous publication [34].
The titer data at 48 h were normalized to those at the beginning of
infection.
Experiments with Replicative Adenovirus Carrying EGFP
gene
An adenovirus packaging plasmid carrying EGFP gene, pPE11-
EGFP, was constructed by incorporating the EGFP expression
cassette into E3 region of pPE11 genome through Gateway system
using the same procedure as described in our previous publication
[35]. And then it was homologous recombined with the plasmids
pXC-let7T, pXC-let7MT, and pXC.1 individually using standard
procedures to generate recombinant adenovirus carrying EGFP,
referred to as SG7011
let7T-EGFP, SG7011
let7MT-EGFP and
WAd5-EGFP, respectively. L-02 and Hep3B cell lines were
cultured in 6-well plates at a density of 4610
5 cells/well. After
24 h, they were infected with SG7011
let7T-EGFP, SG7011
let7MT-
EGFP, and WAd5-EGFP respectively at a MOI of 0.01 for L-02
cells and 0.001 for Hep3B. Three days, 7 days, and 10 days post
infection, cells were observed under fluorescent microscope and
photos were taken.
Adenovirus Cytotoxicity Assay in vitro
L-02, WRL-68, HepG2, Hep3B was planted at a density of
1610
4 in 96-well plates and infected with SG7011
let7T,
SG7011
let7MT and WAd5 at a gradient of MOI from 0.001 to
100 pfu/cell. Cell viability was measured by 3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay according
to the instructions of Cell Proliferation Kit I (Roche Molecular
Biochemicals, Mannheim, Germany).
Animal Experiments
BALB/c nude mice (nu/nu) were purchased from Shanghai
Experimental Animal Center, Chinese Academy of Sciences. All
animal experiments were carried out in adherence with the
National Institutes of Health Guidelines on the Use of Laboratory
Animals and approved by the Second Military Medical University
Committee on Animal Care (EC10-055). Mice were injected s.c. in
the right flank with 1610
7 Hep3B or SMMC-7721 cells in
matrigel (injection volume of 100 ml). When the Hep3B tumors
reached a mean tumor volume of 450 mm
3 or the SMMC-7721
tumor reached a mean tumor volume of 200 mm
3 [volu-
me=(W
26L)/2; W, width; L, length, in cubic millimeters],
animals with the Hep3B or SMMC-7721 xenografts (n=10 per
group) were randomly distributed into three treatment groups,
respectively. The treatment groups were injected intratumorally
with SG7011
let7T or WAd5 five times at a dosing volume of 100 ml
(5610
8 pfu), on the days of 1, 3, 5, 7 and 9 following the initiation.
The control group was intratumorally injected with the placebo
paralleledly [10 mmol/L Tris-HCl (pH 8.0), 2 mmol/L MgCl2,
4% sucrose]. Tumor volumes were measured once weekly after the
first virus injection on day 1.
Histology and Immunohistology
For histologic examination, the explanted tumors were fixed in
10% buffered formalin and then 5-mm paraffin sections were used
for H&E staining or processed for immunohistochemical analysis.
Immunohistochemistry was carried out with anti-adenoviral hexon
protein antibody (Biodesign International, Saco, ME) following the
protocol of the manufacturer as described previously.
Statistical Analysis
Data are expressed as the mean of triplicates 6 standard
deviation unless otherwise stated. Results were compared for
statistical significance by applying t-test. Correlation between
relative let-7 expression and clinicopathologic parameters was
evaluated by using Pearson’s chi-square test. Data were considered
statistically significant when P,0.05.
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